Case Reports in Oncological Medicine

Case Reports in Oncological Medicine / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 7524797 |

Yuridia Evangelina Rodríguez-Rosales, Carlos Eduardo Salazar-Mejía, Blanca Angélica Soto-Martínez, David Hernández-Barajas, Oscar Vidal-Gutiérrez, Gabriela Sofia Gómez-Macías, "Cardiac Tamponade as an Initial Manifestation of Cervical Cancer", Case Reports in Oncological Medicine, vol. 2019, Article ID 7524797, 5 pages, 2019.

Cardiac Tamponade as an Initial Manifestation of Cervical Cancer

Academic Editor: Raffaele Palmirotta
Received09 Oct 2018
Accepted05 Dec 2018
Published09 Jan 2019


Cervical cancer is the second most common malignancy worldwide in women and the third most common cause of cancer death in developing countries. This type of cancer spreads mainly to the lung, the bone, and the brain; however, the pericardium is an unusual site of invasion, which is associated with a poor prognosis. We present a case of a 35-year-old woman with six months of leg edema and abnormal uterine bleeding. During the initial evaluation, cardiac tamponade and a bilateral pleural effusion were found. A left supraclavicular lymphadenopathy was identified on physical examination, while gynecological examination and MRI were irrelevant. Initial cytology of the pericardial fluid showed a poorly differentiated carcinoma, and a cervical biopsy revealed a squamous cell invasive carcinoma. Chemotherapy was started with carboplatin and paclitaxel, but no clinical improvement was noted and the patient died 46 days after arrival. Cardiac tamponade in a young female patient is a harbinger to widen the differential diagnosis to include not only infectious, cardiac, or metabolic etiology but also oncological causes since this will allow appropriate treatment.

1. Introduction

Pericardial metastasis is an unusual manifestation of cervical cancer, generally identified at autopsy [1]. Symptomatic pericardial effusion and cardiac tamponade are usually described in the scenario of recurrent disease after previous treatment with chemotherapy and/or radiotherapy, with very few cases reporting these entities as an initial presentation of cervical cancer [2]. Herein, we present a case of cardiac tamponade as an initial manifestation of a squamous cell carcinoma of the cervix.

2. Case Report

A 35-year-old woman arrived at the emergency department because of rest dyspnea and a 6-month history of lower extremity edema. She had a 3-month history of intermittent abnormal vaginal bleeding. On initial evaluation, the patient was hypoxemic with an oxygen saturation of 80% with room air. Relevant clinical signs were tachycardia and hypotension, decreased heart sounds, and a left supraclavicular lymphadenopathy. A chest X-ray showed a widening of the cardiac silhouette with a bilateral pleural effusion (Figure 1).

Pericardiocentesis was performed and a total of 500 mL of bloody secretion was drained with symptomatic improvement. Pleural fluid was obtained by thoracocentesis, and cytology was positive for a poorly differentiated carcinoma (Figure 2).

An excisional biopsy of the left supraclavicular lymphadenopathy was positive for metastatic squamous cell carcinoma. The cervical biopsy reported a squamous cell carcinoma associated with an intraepithelial high-grade lesion (Figures 3 and 4). CA-125 was 335.5 IU/mL and a simple and contrasted pelvic MRI demonstrated a uterine and cervical absence of tumoral mass; however, peritoneal carcinomatosis was present.

Chemotherapy was begun with carboplatin and paclitaxel. Despite the treatment received during her hospitalization, she again presented a pericardial and pleural effusion with subsequent hemodynamic instability and respiratory failure. Due to the fact that in our center there is no experience in applying intrapericardial sclerotherapy, it was offered to repeat pericardiocentesis; however, this intervention was refused. The patient died 46 days after the initial presentation.

3. Discussion

Cervical cancer is the second most common cancer diagnosed in women worldwide and the third cause of cancer death in developing countries [1, 3, 4]. The main sites for metastasis are the lung, the bone, and the brain [2]. Metastasis to the pericardial sac is an unusual manifestation. It has a reported incidence of 1.2-7% [2, 5, 6], conferring a poor prognosis with an overall survival of 2 to 5 months from diagnosis [2], with the majority of cases discovered at autopsy [710]. To our knowledge, this is the first case of cardiac tamponade as the initial presentation of a squamous cell carcinoma of the cervix.

The most common causes of pericardial effusion with or without tamponade are infections (Coxsackievirus, VEB, CMV, and M. tuberculosis); autoimmune diseases; cancer from lymphatic or hematogenous dissemination (metastasis: melanoma (50%), lung (30%), breast (12%), and lymphoma (12%)) [5, 9, 11, 12]; cardiac diseases (Dressler syndrome, myocarditis, and aortic dissection aneurysm); trauma; metabolic diseases (hypothyroidism, uremia, and ovary hyperstimulation); or drugs (cyclophosphamide, doxorubicin, gemcitabine, cytarabine, fludarabine, docetaxel, isoniazid, hydralazine, and phenytoin) [1, 13].

Maisch et al. analyzed 357 pericardial effusion samples from 1988 to 2008 and identified 68 patients with cancer-associated pericardial effusion. In 42 patients, a malignant pericardial effusion was noted; in 15 patients, it was induced by radiation; in 11, by viral disease; and in 6, with an autoimmune process. From the cancer-associated pericardial effusion, it was found that 52.4% was from lung cancer, 19% breast cancer, 4.8% Hodgkin’s lymphoma, 4.8% colon cancer, 2.4% mesothelioma and esophageal cancer, and 14.2% was of unknown origin undifferentiated cancer [14].

Pericardial effusion as a clinical presentation can be acute (trauma, aortic rupture, and iatrogenic), subacute (uremia or idiopathic), or chronic (constrictive or adhesive). The clinical features are dyspnea, pleuritic pain, cough, fatigue, and syncope. Cardiac tamponade causes hypotension, tachycardia, and decreased heart sounds (Beck triad). The paradoxical pulse is reported as the most sensitive sign (82%) to diagnose cardiac tamponade, followed by tachycardia and elevated jugular venous pressure with a sensitivity of 77% and 76%, respectively [1, 5, 13]. From the initial evaluation, the widening of the cardiac silhouette can be associated with the “water bottle sign” and the concomitant bilateral pleural effusion. The EKG demonstrates low-voltage QRS and nonspecific T wave and ST segment changes. A transthoracic echocardiogram helps assess size, location, and hemodynamic physiology [1].

Pericardiocentesis is a diagnostic and therapeutic procedure. The drainage of the pericardial fluid is assessed daily. The inserted catheter is removed when drainage is less than 30 mL/day. Such a procedure has a greater risk of major complication (1.2%) such as ventricle laceration, pneumothorax, ventricular tachycardia, and bacteremia. In patients with cancer, the risk of recurrence is about 90% [1, 13]. There are many treatment options for pericardial effusion recurrence such as the use of an indwelling catheter with an efficacy of 70-90%, a pericardial window with drainage to the pleural or peritoneal cavity (recurrence of 5-15%), or pericardial sclerosis with chemotherapeutic agents such as cisplatin, bleomycin, or tetracycline [12].

Table 1 summarizes the reported literature regarding cervical cancer associated with pericardial effusion and cardiac tamponade. The mean age for diagnosis was 52 years. Cardiac tamponade was reported with pericardial effusion 6.2 months after the initial diagnosis and mostly in patients with previous treatment. Pericardial tamponade was detected in one patient 5 days after cervical cancer diagnosis with an overall survival of 4 months after pericardiocentesis [9]. Also, Azria et al., in 2011, published a similar case of a 54-year-old woman who initially presented cardiac tamponade, which was posteriorly associated with metastatic cervical adenocarcinoma and who died 33 days after its diagnosis [20].

Author (year)Age at initial presentation (years)Time from diagnosis to pericardial effusionFIGO clinical stage (initial)Previous treatmentPresence of cardiac tamponadeTreatment after diagnosis of pericardial effusionOverall survival

Charles et al. (1997) [15]4624 monthsIIIBRT, hysterectomy+BSOYesPericardial window, CT, doxorubicin8 months
Rieke and Kapp (1988) [5]4923 monthsIIAHysterectomy+BSO, RTNoPericardiocentesis, RT9 months
Rudoff et al. (1989) [16]2721 monthsIIIBRTYesPericardiocentesis, anterior pericardiectomy, cisplatinumNot reported
Nelson and Rose (1993) [9]515 daysIVNoneYesPericardiocentesis/CT cisplatin+RT4 months
613 monthsIIIBRTYesPericardiocentesis, instillation of tetracycline, CT cisplatin, bleomycin, methotrexate alternating with cisplatin and 5FU12 months
Kountz et al. (1993) [17]2810 monthsIIBRT/CTNo/mass in right ventricleNot specified3 months
Jamshed et al. (1996) [6]5732 monthsIBHysterectomy, RTYesPericardiocentesis, pericardial window, RT5 months
Lemus et al. (1998) [10]5324 monthsIBRT, hysterectomy+BSO+superior vaginectomyNo/interventricular septum massRT1 month
4912 monthsIVBRTNo/mass in right ventricleCT 5FU+cisplatin7 months
Senzaki et al. (1999) [18]2816 months Hysterectomy, RT/CTNo/mass in right ventriclePericardiocentesis+intrapericardial cisplatinum1 month
Kim et al. (2008) [19]646 monthsIBCT carboplatin+paclitaxel+concurrent RT pre- and posthysterectomyNo/right atrium mass5-fluorouracil+cisplatin+RT12 months
Kim et al. (2011) [1]526 monthsIVB3 cycles of 5FU, cisplatin+concurrent RTYesPericardiocentesis1 month
Azria et al. (2011) [20]54Initial presentation (cervical adenocarcinoma)IVBNoneYesPericardiocentesis, pericardial window, carboplatin+paclitaxel33 days
Ore et al. (2013) [21]5th decade9 monthsIVBRT, CT topotecan+cisplatinYesPericardiocentesis, pericardial window26 days
Kalra et al. (2014) [2]566 monthsIIIBCarboplatin+paclitaxel+RTYesCT not specified+RTNot reported
Ramegowda et al. (2015) [11]5023 monthsIIIBRT, brachytherapyYesNo treatment4 months
Tsuchida et al. (2016) [22]7815 monthsIIIBRTNo/mass in right ventricleNo treatment1 month

FIGO: International Federation of Gynecology and Obstetrics; CT: chemotherapy; RT: radiotherapy; BSO: bilateral salpingo-oophorectomy; 5FU: 5-fluorouracil.

Within the initial approach of a young woman presenting with cardiac tamponade, an etiology must be identified and cancer should be considered as a possible cause. A correct workup is required to achieve a timely diagnosis, in order to grant the patient the best possible outcome.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.


  1. M. H. Kim, T. H. Lee, C. J. Lee, H. Y. Kim, W. G. Kim, and S. H. Kim, “Malignant pericardial effusion in carcinoma of the uterine cervix,” Korean Journal of Obstetrics & Gynecology, vol. 54, no. 4, pp. 214–217, 2011. View at: Publisher Site | Google Scholar
  2. R. Kalra, R. Pawar, A. Chandna, and R. Panwar, “Metastatic pericardial effusion secondary to squamous cell carcinoma of uterine cervix: a rare case report,” International Journal of Healthcare and Biomedical Research, vol. 2, no. 4, pp. 80–82, 2014. View at: Google Scholar
  3. C. Marth, F. Landoni, S. Mahner et al., “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 28, Supplement 4, pp. iv72–iv83, 2017. View at: Publisher Site | Google Scholar
  4. P. Petignat and M. Roy, “Diagnosis and management of cervical cancer,” BMJ, vol. 335, no. 7623, pp. 765–768, 2007. View at: Publisher Site | Google Scholar
  5. J. W. Rieke and D. S. Kapp, “Successful management of malignant pericardial effusion in metastatic squamous cell carcinoma of the uterine cervix,” Gynecologic Oncology, vol. 31, no. 2, pp. 338–351, 1988. View at: Publisher Site | Google Scholar
  6. A. Jamshed, Y. Khafaga, G. el-Husseiny, A. J. Gray, and M. Manji, “Pericardial metastasis in carcinoma of the uterine cervix,” Gynecologic Oncology, vol. 61, no. 3, pp. 451–453, 1996. View at: Publisher Site | Google Scholar
  7. W. B. Lockwood and W. L. Broghamer, “The changing prevalence of secondary cardiac neoplasms as related to cancer therapy,” Cancer, vol. 45, no. 10, pp. 2659–2662, 1980. View at: Publisher Site | Google Scholar
  8. D. Dequanter, P. Lothaire, T. Berghmans, and J. P. Sculier, “Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival,” Annals of Surgical Oncology, vol. 15, no. 11, pp. 3268–3271, 2008. View at: Publisher Site | Google Scholar
  9. B. E. Nelson and P. G. Rose, “Malignant pericardial effusion from squamous cell cancer of the cervix,” Journal of Surgical Oncology, vol. 52, no. 3, pp. 203–206, 1993. View at: Publisher Site | Google Scholar
  10. J. F. Lemus, G. Abdulhay, C. Sobolewski, and V. R. Risch, “Cardiac metastasis from carcinoma of the cervix: report of two cases,” Gynecologic Oncology, vol. 69, no. 3, pp. 264–268, 1998. View at: Publisher Site | Google Scholar
  11. K. S. Ramegowda, N. Agrawal, P. Bhatt, and C. N. Manjunath, “Cardiac metastases from a gynecological malignancy presenting with tamponade: a rare and potentially life threatening medical emergency,” Journal of Indian College of Cardiology, vol. 5, no. 1, pp. 86–89, 2015. View at: Publisher Site | Google Scholar
  12. K. Reynen, U. Köckeritz, and R. H. Strasser, “Metastases to the heart,” Annals of Oncology, vol. 15, no. 3, pp. 375–381, 2004. View at: Publisher Site | Google Scholar
  13. M. Petrofsky, “Management of malignant pericardial effusion,” Journal of the Advanced Practitioner in Oncology, vol. 5, no. 4, pp. 281–289, 2014. View at: Publisher Site | Google Scholar
  14. B. Maisch, A. Ristic, and S. Pankuweit, “Evaluation and management of pericardial effusion in patients with neoplastic disease,” Progress in Cardiovascular Diseases, vol. 53, no. 2, pp. 157–163, 2010. View at: Publisher Site | Google Scholar
  15. E. H. Charles, J. Condori, and S. Sall, “Metastasis to the pericardium from squamous cell carcinoma of the cervix,” American Journal of Obstetrics & Gynecology, vol. 129, no. 3, pp. 349–351, 1977. View at: Publisher Site | Google Scholar
  16. J. Rudoff, R. Percy, G. Benrubi, and M. L. Ostrowski, “Recurrent squamous cell carcinoma of the cervix presenting as cardiac tamponade: case report and subject review,” Gynecologic Oncology, vol. 34, no. 2, pp. 226–231, 1989. View at: Publisher Site | Google Scholar
  17. D. S. Kountz, “Isolated cardiac metastasis from cervical carcinoma: presentation as acute anteroseptal myocardial infarction,” Southern Medical Journal, vol. 86, no. 2, pp. 228–230, 1993. View at: Publisher Site | Google Scholar
  18. H. Senzaki, Y. Uemura, D. Yamamoto et al., “Right intraventricular metastasis of squamous cell carcinoma of the uterine cervix: an autopsy case and literature review,” Pathology International, vol. 49, no. 5, pp. 447–452, 1999. View at: Publisher Site | Google Scholar
  19. H. S. Kim, N. H. Park, and S. B. Kang, “Rare metastases of recurrent cervical cancer to the pericardium and abdominal muscle,” Archives of Gynecology and Obstetrics, vol. 278, no. 5, pp. 479–482, 2008. View at: Publisher Site | Google Scholar
  20. E. Azria, M. Dufeu, P. Fernandez, F. Walker, and D. Luton, “Cervical adenocarcinoma presenting as a cardiac tamponade in a 57-year-old woman: a case report,” Journal of Medical Case Reports, vol. 5, no. 1, 2011. View at: Publisher Site | Google Scholar
  21. R. M. Ore, B. G. Reed, and C. A. Leath III, “Malignant pericardial effusion and pericardial tumor involvement secondary to cervical cancer,” Military Medicine, vol. 178, no. 1, pp. e130–e132, 2013. View at: Publisher Site | Google Scholar
  22. K. Tsuchida, T. Oike, T. Ohtsuka et al., “Solitary cardiac metastasis of uterine cervical cancer with antemortem diagnosis: a case report and literature review,” Oncology Letters, vol. 11, no. 5, pp. 3337–3341, 2016. View at: Publisher Site | Google Scholar

Copyright © 2019 Yuridia Evangelina Rodríguez-Rosales et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles